Mabtas 100mg/10ml Injection

Mabtas 100mg/10ml Injection contains Rituximab as an active ingredient that is a monoclonal antibody. It is used in the treatment of certain types of blood cancers such as chronic lymphocytic leukemia, non-Hodgkin lymphoma, and autoimmune disorders like rheumatoid arthritis, granulomatosis with polyangiitis and microscopic polyangiitis. As it is a monoclonal antibody so it works by targeting the unusual activity of immune cells (B cells) in certain types of cancers and rheumatoid arthritis. It should be given by healthcare professional only do not self-administer this injection.

• Rheumatoid arthritis
• Blood cancer (Chronic lymphocytic leukemia)
• Non-Hodgkin lymphoma (NHL)
• Granulomatosis with polyangiitis
• Microscopic polyangiitis  

Mabtas 100mg/10ml Injection can cause multiple side effects, most of which are mild to moderate and often temporary. Patients are advised to inform their healthcare provider immediately if symptoms stays for prolonged period of time.  

Common side effects include:

• Headache
• Weakness
• Infection
• Chills
• Decreased white blood cell count (neutrophils)
• Fever
• Infusion site reaction
• Lymphopenia
• Abdominal pain
• Back pain

• The recommended dose of Mabtas 100mg/10ml Injection may vary according to the type of disease, as well as age, weight, and other health factors of the patients.
• It should be given intravenously by a doctor or experienced nurse. Don't self- administer the injection and don't double the dose to compensate for the missed dose.
  

Mabtas 100mg/10ml Injection contains Rituximab as an active ingredient that is a monoclonal antibody. As it is a monoclonal antibody so it works by targeting the unusual activity of immune cells (B cells) in certain types of cancers and rheumatoid arthritis.

• Chisari, C. G., Sgarlata, E., Arena, S., Toscano, S., Luca, M., & Patti, F. (2022). Rituximab for the treatment of multiple sclerosis: a review. Journal of neurology, 269(1), 159-183. https://pubmed.ncbi.nlm.nih.gov/33416999/
• Plosker, G. L., & Figgitt, D. P. (2003). Rituximab: a review of its use in non-Hodgkin’s lymphoma and chronic lymphocytic leukaemia. Drugs, 63(8), 803-843. https://pubmed.ncbi.nlm.nih.gov/12662126/
• Non-Hodgkin lymphoma (NHL), rheumatoid arthritis, blood cancer (chronic lymphocytic leukemia), granulomatosis with polyangiitis and microscopic polyangiitis.
• Mok, C. C. (2014). Rituximab for the treatment of rheumatoid arthritis: an update. Drug design, development and therapy, 87-100. https://pmc.ncbi.nlm.nih.gov/articles/PMC3883598/
• Provan, D., Butler, T., Evangelista, M. L., Amadori, S., Newland, A. C., & Stasi, R. (2007). Activity and safety profile of low-dose rituximab for the treatment of autoimmune cytopenias in adults. haematologica, 92(12), 1695-1698. https://pubmed.ncbi.nlm.nih.gov/18055995/
• Zaja, F., Battista, M. L., Pirrotta, M. T., Palmieri, S., Montagna, M., Vianelli, N., ... & Fanin, R. (2008). Lower dose rituximab is active in adult’s patients with idiopathic thrombocytopenic purpura. haematologica, 93(6), 930-933. https://pubmed.ncbi.nlm.nih.gov/18403395/
• Bredemeier, M., de Oliveira, F. K., & Rocha, C. M. (2014). Low‐versus high‐dose rituximab for rheumatoid arthritis: a systematic review and meta‐analysis. Arthritis care & research, 66(2), 228-235 https://pubmed.ncbi.nlm.nih.gov/23983134/